Journal Article Summary
This article investigates how genetic factors influence the effectiveness of aspirin in patients who have suffered an acute ischemic stroke (AIS). Aspirin is a widely used medication for preventing recurrent strokes, but its effectiveness can vary greatly among individuals. Understanding these differences is crucial because some patients may not respond well to aspirin, leading to poor outcomes. The study aims to develop a pharmacogenetic polygenic response score (PgxRS) that can help predict adverse outcomes in these patients based on their genetic makeup.
The researchers conducted a retrospective study involving 828 AIS patients who were treated with aspirin. They analyzed 15 specific genetic variants, known as single nucleotide polymorphisms (SNPs), that are related to how aspirin works in the body. The study found that the rs1045642GG genotype in the ABCB1 gene was linked to a lower risk of poor outcomes, while the rs1371097T allele in the P2Y1 gene was associated with a higher risk. The predictive model created from these findings showed moderate accuracy in forecasting adverse outcomes, suggesting that genetic testing could help tailor aspirin therapy for individual patients.
However, the study has limitations that should be considered. It was conducted at a single center and involved only a specific population, which may limit the applicability of the results to other groups. Additionally, the study did not control for the use of other antiplatelet medications, which could affect the results. Patients and caregivers should discuss these findings with healthcare professionals, especially regarding the potential for genetic testing to inform treatment decisions and improve outcomes in stroke management.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Ma Rui-Nan, Zhang Dong, Li Zhi-Zhang, Ding Ying, Zhang Xiao-Guang, Xue Jie, Ci Dan-Zhuoma, Bai Yue-Ying, et al.. Pharmacogenetics polygenic response score predicts outcomes in aspirin-treated stroke patients. Frontiers in Pharmacology 2025. DOI: 10.3389/fphar.2025.1519383. PMID: 40290439. PMCID: PMC12023276.
Featured Pill Pals Product
OTC 1000 (1,000) Count Low Dose Aspirin 81mg for Adults and Children 12 years and over --- Generic For Bayer Low Dose --- Time Cap Labs
1000 (1,000) Count Low Dose Aspirin 81mg for Adults and Children 12 years and over --- Generic For Bayer Low Dose --- Time Cap Labs is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. No prescription required for eligible over-the-counter purchases.
